Publication date: Aug 06, 2024
The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of COVID-19. It will also estimate the impact of non-invasive Neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae. The main question it aim to answer is: – Is non-invasive Neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of COVID-19? Researchers will compare non-invasive Neuromodulation to a placebo (treatment with the machine turned off). Participants will: * Be evaluated before starting treatment. * Be evaluated 3 weeks after. * Be evaluated at 5 weeks, or 15 sessions or completion of treatment. * Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.
Concepts | Keywords |
---|---|
Covid | COVID-19 |
Olfactory | NON INVASIVE NEUROMODULATION |
Therapy | SMELL |
Weeks |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | covid-19 |
disease | MESH | Sequelae |
disease | VO | effectiveness |
disease | IDO | quality |
disease | VO | effective |
disease | IDO | history |
disease | MESH | musculoskeletal disease |